1. Home
  2. AEVA vs FTRE Comparison

AEVA vs FTRE Comparison

Compare AEVA & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aeva Technologies Inc.

AEVA

Aeva Technologies Inc.

HOLD

Current Price

$12.69

Market Cap

819.5M

ML Signal

HOLD

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$8.99

Market Cap

829.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEVA
FTRE
Founded
2019
1996
Country
United States
United States
Employees
276
N/A
Industry
Auto Parts:O.E.M.
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
819.5M
829.3M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
AEVA
FTRE
Price
$12.69
$8.99
Analyst Decision
Strong Buy
Buy
Analyst Count
4
9
Target Price
$26.50
$15.39
AVG Volume (30 Days)
1.3M
1.2M
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,723,400,000.00
Revenue This Year
$85.37
N/A
Revenue Next Year
$132.72
$3.01
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.00
52 Week Low
$5.81
$3.97
52 Week High
$38.79
$18.67

Technical Indicators

Market Signals
Indicator
AEVA
FTRE
Relative Strength Index (RSI) 42.26 38.52
Support Level $12.44 $8.85
Resistance Level $17.51 $11.22
Average True Range (ATR) 1.33 0.64
MACD -0.26 0.13
Stochastic Oscillator 24.00 30.43

Price Performance

Historical Comparison
AEVA
FTRE

About AEVA Aeva Technologies Inc.

Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Share on Social Networks: